Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1050

Sort by

Sort Order Select

Journal Articles

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard Wells, James McCloskey, II, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona

Blood (2020) 136 (6): 674–683.

https://doi.org/10.1182/blood.2019004143

Published: 2020

Journal Articles

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Tanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, Raymond Reynolds, Hanna Scholze, Annamalai Selvakumar, Teresa Vizconde, Bhumesh Savalia, Vadim Dyomin, Christoph Weigel, Christopher C. Oakes, Alicia Alonso, Olivier Elemento, Heng Pan, Jude M. Phillip, Richard J. O’Reilly, Benjamin E. Gewurz, Ethel Cesarman, Lisa Giulino-Roth

Blood (2020) 135 (21): 1870–1881.

https://doi.org/10.1182/blood.2019004126

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

Knockdown of HNF4A Gene Increases Fetal Hemoglobin Synthesis in Hudep-2

Ingrid Grazielle Sousa, BSc, MSc, Priscila Keiko Matsumoto Martin, PhD, Dulcinéia Martins de Albuquerque, BSc, PhD, Carolina Lanaro, BSc, PhD, Ryo Kurita, PhD, Yukio Nakamura, MD PhD, Fernando Ferreira Costa, MD PhD

Blood (2019) 134 (Supplement_1): 968.

https://doi.org/10.1182/blood-2019-130920

Published: 2019

Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Blood (2019) 134 (Supplement_1): 846.

https://doi.org/10.1182/blood-2019-122980

Published: 2019

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 734.

https://doi.org/10.1182/blood-2019-128648

Published: 2019

Journal Articles

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 738.

https://doi.org/10.1182/blood-2019-128909

Published: 2019

Journal Articles

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Lisa Pleyer, Michael Leisch, MD, Alexandra Kourakli, MD PhD, Eric Padron, MD, Jaroslaw P. Maciejewski, MD PhD, Blanca Xicoy, MD MSc, Jennifer Kaivers, MD, Johanna Ungerstedt, MD PhD, Sonja Heibl, MD, Peristera Patiou, MD, Anthony M. Hunter, MD, Elvira Mora, MD, Klaus Geissler, MD, Maria Dimou, MD PhD, María-José Jimenez, MD, David Kiesl, MD, Nora-Athina Viniou, MD PhD, Bhumika J. Patel, MD, Montserrat Arnan Sangerman, Peter Valent, MD, Christoforos Roubakis, MD, Teresa Bernal del Castillo, MD PhD, Athanasios Galanopoulos, MD PhD, Marisa Calabuig, MD, Nicolas Bonadies, MD, Antonio Medina de Almeida, MD PhD, Jaroslav Cermak, MD PhD, Andres Jerez, Julia Montoro, MD, Albert Cortés, Alejandro Avendaño Pita, MD, Bernardo López Andrade, MD, Eva Hellstrom Lindberg, MD PhD, Ulrich Germing, MD, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Argiris Symeonidis, MD PhD, Guillermo F. Sanz, MD PhD, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 844.

https://doi.org/10.1182/blood-2019-123941

Published: 2019

Journal Articles

Regulation of Fetal Hemoglobin through the Insulin Signaling Pathway

Alireza Paikari, MD, Yankai Zhang, PhD, Alicia Chang, MD, Ankush Goyal, MA, Evadnie Rampersaud, PhD, Jonathan M. Flanagan, PhD, Mitchell J. Weiss, MD, PhD, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 811.

https://doi.org/10.1182/blood-2019-131313

Published: 2019

Journal Articles

Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine Model

Haley E. Ramsey, PhDMSc, Maria Arrate, MSc, Londa Fuller, Agnieszka E. Gorska, MSc, Kelli Boyd, DVM, PhD, Melissa A. Fischer, MSc, PhD, Aram Oganesian, PhD, Mohammad Azab, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1376.

https://doi.org/10.1182/blood-2019-125899

Published: 2019

Journal Articles

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

Brianna N Smith, MD MS, Dan Cojocari, PhD BSc, Julie J Purkal, MA, Maria Arrate, MSc, Haley E. Ramsey, PhDMSc, Joel D. Leverson, PhD, Erwin Boghaert, MS, MD, Darren C. Phillips, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1380.

https://doi.org/10.1182/blood-2019-123068

Published: 2019

Journal Articles

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Elizabeth A. Griffiths, MD, Hagop M. Kantarjian, MD, Casey L. O'Connell, MD, Karen W.L. Yee, MD, Wendy Stock, MD, Naval G. Daver, MD, Elias Jabbour, MD, Ellen K. Ritchie, MD, Jean-Pierre Issa, MD, Katherine J. Walsh, MD, David A. Rizzieri, MD, Scott D. Lunin, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1319.

https://doi.org/10.1182/blood-2019-131394

Published: 2019

Journal Articles

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Tongyuan Xue, MD, Marissa Del Real, PhD, Emanuela Marcucci, Candida Toribio, Sonia Maryam Setayesh, Stephen J Forman, MD, David A Horne, PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 1383.

https://doi.org/10.1182/blood-2019-121486

Published: 2019

Journal Articles

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Lauren Pommert, MDMS, Deepa Bhojwani, MD, Richard Sposto, PhD, Ellynore Florendo, Eric Schafer, MD, Nathan Gossai, MD, Van Thu Huynh, MD, Sridhar Rao, MD PhD, Michael J. Burke, MD

Blood (2019) 134 (Supplement_1): 1325.

https://doi.org/10.1182/blood-2019-127298

Published: 2019

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

Myrna Nahas, MD, Dina Stroopinsky, PhD, Marzia Capelletti, PhD MBBS, Jacalyn Rosenblatt, MD, Shira Orr, PhD, Haider Ghiasuddin, Adam Morin, Jessica Liegel, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 1386.

https://doi.org/10.1182/blood-2019-122438

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 570.

https://doi.org/10.1182/blood-2019-128178

Published: 2019

Journal Articles

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Qing Li, MD, Yunfan Yang, MD, Yu Wu, MD

Blood (2019) 134 (Supplement_1): 536.

https://doi.org/10.1182/blood-2019-123876

Published: 2019

NARROW

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Knockdown of HNF4A Gene Increases Fetal Hemoglobin Synthesis in Hudep-2

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Regulation of Fetal Hemoglobin through the Insulin Signaling Pathway

Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine Model

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only